Beta Bionics, Inc. (NASDAQ:BBNX) Q1 2026 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q1 2026 Earnings Call Transcript April 21, 2026Beta Bionics, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.53.
Beta Bionics Inc. (BBNX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Soleus Capital Guy Levy | 4,393,714 | $68,849,498 | +1% | 2.37% |
| 2. | Point72 Asset Management Steve Cohen | 2,254,683 | $35,330,883 | -11% | 0.04% |
| 3. | Vestal Point Capital Ryan Wilder | 1,600,000 | $25,072,000 | -28% | 0.59% |
| 4. | Deerfield Management James E. Flynn | 1,324,000 | $20,747,080 | 0.22% | |
| 5. | Eversept Partners Kamran Moghtaderi | 1,249,441 | $19,578,740 | -12% | 1.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.00 | 33,350 | $566,950.00 | 59,019 | 2025-01-31 | Filing | |
| $17.00 | 1,000,000 | $17,000,000.00 | 3,901,599 | 2025-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.13 | 30,779 | $619,639.75 | 56,479 | 2026-09-16 | Filing | |
| $22.00 | 2,650 | $58,300.00 | 177,390 | 2026-09-16 | Filing | |
| $15.52 | 775 | $12,028.00 | 86,382 | 2026-09-14 | Filing | |
| $18.46 | 36,870 | $680,723.44 | 87,157 | 2026-09-09 | Filing | |
| $20.08 | 5,641 | $113,258.87 | 398,429 | 2026-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,253,673 | $98,053,951 | 1.31% | |
| 2. | 4,266,822 | $66,861,101 | 0% | |
| 3. | 3,708,043 | $58,105,034 | 9.47% | |
| 4. | 3,340,171 | $52,340,479 | 0% | |
| 5. | 1,782,346 | $27,929,362 | 0% |
News See All
Beta Bionics, Inc. (NASDAQ:BBNX) Q4 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q4 2025 Earnings Call Transcript February 18, 2026 Operator: Good day, and thank you for standing by. Welcome to the Beta Bionics Inc.
Beta Bionics, Inc. (NASDAQ:BBNX) Q3 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q3 2025 Earnings Call Transcript October 28, 2025Beta Bionics, Inc. beats earnings expectations. Reported EPS is $-0.33, expectations were $-0.45.
Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook
Beta Bionics Inc. (NASDAQ:BBNX) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Beta Bionics, Inc. (NASDAQ:BBNX) Q2 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q2 2025 Earnings Call Transcript July 31, 2025 Operator: Good afternoon, and welcome to the Beta Bionics Second Quarter 2025 Earnings Conference Call.
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc.
Wolfe Research Initiates Coverage of Beta Bionics (BBNX) Stock with Outperform Rating
On May 30, Wolfe Research began coverage on Beta Bionics, Inc. (NASDAQ:BBNX)’s stock with an “Outperform” rating and a price objective of $20, as reported by The Fly.
Beta Bionics, Inc. (NASDAQ:BBNX) Q1 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q1 2025 Earnings Call Transcript May 10, 2025 Operator: Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call.
Hedge Fund Resource Center